Press release
Diarrhea Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Curious about the latest updates in the Diarrhea Pipeline? Click here to explore the therapies and trials making headlines @ Diarrhea Pipeline Outlook Report [https://www.delveinsight.com/sample-request/diarrhea-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Diarrhea Pipeline Report
* On 22 September 2025, Immuron Ltd . conducted a study to investigate if Travelan Registered protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli (ETEC) strain H10407.
* DelveInsight's Diarrhea Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Diarrhea treatment.
* The leading Diarrhea Companies such as RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.
* Promising Diarrhea Therapies such as Carbowhite, Nitazoxanide, OPT-80, Racecadotril plus ORS, Rifaximin, Xifaxan Registered , Elsiglutide and others.
Want to know which companies are leading innovation in Diarrhea? Dive into the full pipeline insights @ Diarrhea Clinical Trials Assessment [https://www.delveinsight.com/sample-request/diarrhea-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Diarrhea Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Diarrhea Pipeline Report also highlights the unmet needs with respect to the Diarrhea.
Diarrhea Overview
Diarrhea is having three or more loose or liquid stools (poos) in one day, or more frequently than normal. Diarrhea episodes are often caused by a stomach bug (gastroenteritis) and clear up on their own in a few days. However, there are many other causes of diarrhea. Most diarrhea is mild, but it can also be severe even needing admission to hospital. Diarrhea is the augmentation of water content in stools because of an imbalance in the normal functioning of physiologic processes of the small and large intestine responsible for the absorption of various ions, other substrates, and consequently water. Acute diarrhea is described as the acute onset of three or more loose or watery stools a day lasting for 14 days or less.
Diarrhea Emerging Drugs Profile
* VE303: Vedanta Biosciences, Inc.
VE303 is an orally administered, rationally-designed, defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under CGMP conditions. Currently, the drug is in clinical trial Phase III stage for the treatment diarrhea disease.
RHB-102: RedHill Biopharma Limited
RHB-102 is a proprietary, bimodal release, once-daily oral pill formulation of the antiemetic drug ondansetron, targeting several gastrointestinal indications. RHB-102 24 mg is intended to provide patients with relief from nausea and vomiting symptoms for a full 24-hour period with a single oral tablet. Currently, the drug is in clinical trial Phase II stage for the treatment diarrhea disease.
VR-AD-1005: Hunazine Biotech
VR-AD-1005, a novel antidiarrheal investigational drug for the innovative treatment of severe diarrhea of cholera. VR-AD-1005 is intended to work by reducing the volume of liquid stool produced by the intestine when suffering from the diarrheal pathogen. The drug works within the intestine without affecting its motility and does not induce constipation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of severe diarrhea of cholera.
ShigETEC: Eveliqure Biotechnologies GmbH
ShigETEC is an orally administered vaccine that induces broad protection against Shigella in a serotype-independent fashion and additionally against ETEC, two major pathogens responsible for diarrhoeal diseases. Based on preclinical data generated by Eveliqure over the last 5 years, it has the potential to be a best-in-class diarrhoea vaccine that targets both travelers and populations in low- and middle-income countries. Currently, the drug is in clinical trial Phase I stage for the treatment of diarrhea disease.
If you're tracking ongoing Diarrhea Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Diarrhea Treatment Drugs [https://www.delveinsight.com/sample-request/diarrhea-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Diarrhea Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Diarrhea with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diarrhea Treatment.
* Diarrhea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Diarrhea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diarrhea market.
Diarrhea Companies
RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.
Diarrhea Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Diarrhea Products have been categorized under various Molecule types such as,
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Diarrhea Pipeline Report covers it all - check it out now @ Diarrhea Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/diarrhea-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Diarrhea Pipeline Report
* Coverage- Global
* Diarrhea Companies- RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.
* Diarrhea Therapies- Carbowhite, Nitazoxanide, OPT-80, Racecadotril plus ORS, Rifaximin, Xifaxan Registered , Elsiglutide and others.
* Diarrhea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Diarrhea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Diarrhea Treatment landscape in this detailed analysis @ Diarrhea Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/diarrhea-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Diarrhea: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Diarrhea - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* VE303: Vedanta Biosciences, Inc.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* VR-AD-1005: Hunazine Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ShigETEC: Eveliqure Biotechnologies GmbH
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Diarrhea Key Companies
* Diarrhea Key Products
* Diarrhea - Unmet Needs
* Diarrhea - Market Drivers and Barriers
* Diarrhea - Future Perspectives and Conclusion
* Diarrhea Analyst Views
* Diarrhea Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diarrhea-pipeline-drugs-report-2025-emerging-therapies-clinical-developments-and-drug-insights-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diarrhea-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diarrhea Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight here
News-ID: 4216926 • Views: …
More Releases from ABNewswire
Planning the Perfect Holiday Gathering in Mineral Wells, TX for Memorable Celebr …
Holidays are occasions to spend with people you love as well as have an opportunity to swap stories that will be a lifetime memory. In the Mineral Wells, TX the season of celebrations gained a festivity different touch. It is available on small town, locality and home-town atmosphere which also makes it the best at celebrating memorable moments. You can have your family dinner, a basic friend get-togathering, or even…
High-Performance Fibers Market to Surpass USD 26.45 Billion by 2030, Driven by R …
Mordor Intelligence's new study on the "High-Performance Fibers Market" presents a thorough evaluation of the market's trajectory, including major trends and future outlook.
High-Performance Fibers Market to Surpass USD 26.45 Billion by 2030, Driven by Rising Carbon Fiber Adoption
Mordor Intelligence's new study on the "High-Performance Fibers Market" presents a thorough evaluation of the market's trajectory, including major trends and future outlook.
High-Performance Fibers Market Overview:
The global High-Performance Fibers Market is poised for…
Cloud Gaming Market Forecast to Reach USD 39.57 Billion by 2030, Driven by 5G Ex …
Mordor Intelligence has published a new report on the Cloud Gaming Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Cloud Gaming Market Overview
The Cloud gaming market [https://www.mordorintelligence.com/industry-reports/cloud-gaming-market?utm_source=abnewswire%20] size is estimated at USD 5.32 billion in 2025 and is forecast to reach USD 39.57 billion by 2030, expanding at a 49.35% CAGR. Cloud Gaming Market share is expanding as more games launch on cloud platforms and telecom operators…
BOPP Films Market Forecast to Reach USD 17.99 Billion by 2030, Driven by Packagi …
Mordor Intelligence has published a new report on the BOPP Films Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
BOPP Films Market Overview
The global BOPP films market size [https://www.mordorintelligence.com/industry-reports/bopp-films-market?utm_source=abnewswire] stands at USD 14.22 billion in 2025 and is projected to advance to USD 17.99 billion by 2030, translating into a 4.82% CAGR over the forecast period. The Asia-Pacific region holds the largest BOPP Films Market share, fueled…
More Releases for Diarrhea
Traveler's Diarrhea Market to Reach USD 1.6 Billion by 2034
Traveler's diarrhea (TD) is the most common illness affecting international travelers, typically caused by bacterial pathogens such as Escherichia coli (ETEC), Shigella, Campylobacter, and Salmonella, though viruses and parasites also contribute. It affects millions of travelers annually, especially in developing regions of Asia, Africa, and Latin America.
While TD is usually self-limiting, it can disrupt travel, cause severe dehydration, and lead to complications in vulnerable populations. The growing global travel industry,…
Why does eating too much Maltitol cause diarrhea?
Why does too much maltitol result in diarrhea? Does all sugar alcohols give you diarrhea? Are all kinds of sugar substitutes added to food healthy?
Image: https://www.justgood-health.com/uploads/Erythritol2.jpgImage: https://www.justgood-health.com/uploads/Sugar-alcohol.jpg
Today we're going to talk about it. What exactly is sugar alcohol? Sugar alcohols [https://www.justgood-health.com/] are polyols that are generally made from a wide range of corresponding sugars. For example, the xylose reduction is the familiar xylitol.In addition, the sugar alcohols currently under development…
Traveler's Diarrhea Treatment Market Research Report 2024
The global Traveler's Diarrhea Treatment market was valued at US$ 785.4 million in 2023 and is anticipated to reach US$ 1007.4 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-12Y2699/Global_Traveler_s_Diarrhea_Treatment_Market_Insights_Forecast_to_2028
Traveler's diarrhea (TD) is a stomach and intestinal infection. TD is defined as the passage of unformed stool (one or more by some definitions, three or more by others) while traveling. It may be…
Understanding Traveler's Diarrhea Treatment Trends
Traveler's diarrhea is a common ailment that can disrupt travel plans and cause discomfort to millions of tourists worldwide. However, this challenge has spurred the growth of the global traveler's diarrhea treatment market, which is expected to expand significantly during the forecast period of 2024-2032. In this comprehensive guide, we will delve deeper into the market's dynamics, exploring its size, share, trends, industry segmentation, outlook, and various factors driving its…
Travelers Diarrhea Treatment Market Size, Share, Growth | Report, 2026
Latest Updated Report 2023, The Global Travelers Diarrhea Treatment Market to Growing A CAGR of % during forecast period of 2023-2026. The Market is segmented by Global Travelers Diarrhea Treatment Market Breakdown by Application (Medical) by Type (General Type) and by Geography (North America, South America, Europe, Asia Pacific, MEA).
The Travelers Diarrhea Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It…
Carcinoid Syndrome Diarrhea Treatment Market - Increasing prevalence of rare car …
Carcinoid Syndrome Diarrhea Treatment Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Carcinoid Syndrome Diarrhea Treatment Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor…
